Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 16c

Go back to Viridian Therapeutics, Inc. (VRDN) Misses Q2 EPS by 16c

Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

August 15, 2022 7:02 AM EDT

- Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in... More